

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Aug 2026

### Effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women: a single-blind randomized controlled trial

#### Protocol summary

##### Study aim

To assess the effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women

##### Design

This is a single-blind randomized clinical trial with control group, phase III, in which eligible patients will be randomly assigned through the drawing of lots to the intervention and control groups

##### Settings and conduct

This study will be performed in the Fatemieh Hospital in Hamadan city on 172 primiparous pregnant women. The patients will be randomly assigned to the intervention and control groups through the drawing of lots. This trial will be single-blinded.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age of 18 to 45 years; Primiparous; Singleton; Gestational age of 20 weeks; Exclusion criteria: History of hypertension; Affected with chronic diseases such as thyroid disorder and diabetes; Using selenium supplement;

##### Intervention groups

Intervention group: Supplements (iron tablets and multivitamin capsules and calcium tablets) from 16th weeks of pregnancy once a day for 16 weeks plus L-arginine 500 mg tablets (manufactured by Karen Pharmaceutical Co.) from 20th weeks of pregnancy once a day for 12 weeks Control group: Supplements (iron tablets and multivitamin capsules and calcium tablets) from 16th weeks of pregnancy once a day for 16 weeks

##### Main outcome variables

Primary outcome: Preeclampsia

#### General information

##### Reason for update

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20120215009014N416**

Registration date: **2022-01-12, 1400/10/22**

Registration timing: **prospective**

Last update: **2022-01-12, 1400/10/22**

Update count: **0**

#### Registration date

2022-01-12, 1400/10/22

#### Registrant information

##### Name

Jalal Poorolajal

##### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 1838 0090

##### Email address

poorolajal@umsha.ac.ir

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2022-01-30, 1400/11/10

#### Expected recruitment end date

2023-01-30, 1401/11/10

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

|                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                                                                                                                  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women: a single-blind randomized controlled trial                                                                                                                                                                                                    |  | Sciences                                                                                                                                                                                                                                                                         |  |
| <b>Public title</b>                                                                                                                                                                                                                                                                                                                                      |  | <b>Street address</b>                                                                                                                                                                                                                                                            |  |
| Effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women                                                                                                                                                                                                                                                |  | Vice-chancellor for Research and Technology,<br>Hamadan University of Medical Sciences, Shahid Fahmideh Ave                                                                                                                                                                      |  |
| <b>Purpose</b>                                                                                                                                                                                                                                                                                                                                           |  | <b>City</b>                                                                                                                                                                                                                                                                      |  |
| Prevention                                                                                                                                                                                                                                                                                                                                               |  | Hamadan                                                                                                                                                                                                                                                                          |  |
| <b>Inclusion/Exclusion criteria</b>                                                                                                                                                                                                                                                                                                                      |  | <b>Province</b>                                                                                                                                                                                                                                                                  |  |
| <b>Inclusion criteria:</b>                                                                                                                                                                                                                                                                                                                               |  | Hamadan                                                                                                                                                                                                                                                                          |  |
| Age of 18 to 45 years; Primiparous: Singleton;<br>Gestational age of 20 weeks;                                                                                                                                                                                                                                                                           |  | <b>Postal code</b>                                                                                                                                                                                                                                                               |  |
| <b>Exclusion criteria:</b>                                                                                                                                                                                                                                                                                                                               |  | 6517838695                                                                                                                                                                                                                                                                       |  |
| History of hypertension; Affected with chronic diseases such as thyroid disorder and diabetes; Using selenium supplement;                                                                                                                                                                                                                                |  | <b>Approval date</b>                                                                                                                                                                                                                                                             |  |
| <b>Age</b>                                                                                                                                                                                                                                                                                                                                               |  | 2021-10-16, 1400/07/24                                                                                                                                                                                                                                                           |  |
| From <b>18 years</b> old to <b>45 years</b> old                                                                                                                                                                                                                                                                                                          |  | <b>Ethics committee reference number</b>                                                                                                                                                                                                                                         |  |
| <b>Gender</b>                                                                                                                                                                                                                                                                                                                                            |  | IR.UMSHA.REC.1400.538                                                                                                                                                                                                                                                            |  |
| Female                                                                                                                                                                                                                                                                                                                                                   |  | <b>Health conditions studied</b>                                                                                                                                                                                                                                                 |  |
| <b>Phase</b>                                                                                                                                                                                                                                                                                                                                             |  | <b>1</b>                                                                                                                                                                                                                                                                         |  |
| 3                                                                                                                                                                                                                                                                                                                                                        |  | <b>Description of health condition studied</b>                                                                                                                                                                                                                                   |  |
| <b>Groups that have been masked</b>                                                                                                                                                                                                                                                                                                                      |  | Pre-eclampsia                                                                                                                                                                                                                                                                    |  |
| <ul style="list-style-type: none"> <li>Outcome assessor</li> </ul>                                                                                                                                                                                                                                                                                       |  | <b>ICD-10 code</b>                                                                                                                                                                                                                                                               |  |
| <b>Sample size</b>                                                                                                                                                                                                                                                                                                                                       |  | O14                                                                                                                                                                                                                                                                              |  |
| Target sample size: <b>172</b>                                                                                                                                                                                                                                                                                                                           |  | <b>ICD-10 code description</b>                                                                                                                                                                                                                                                   |  |
| <b>Randomization (investigator's opinion)</b>                                                                                                                                                                                                                                                                                                            |  | Pre-eclampsia                                                                                                                                                                                                                                                                    |  |
| Randomized                                                                                                                                                                                                                                                                                                                                               |  | <b>Primary outcomes</b>                                                                                                                                                                                                                                                          |  |
| <b>Randomization description</b>                                                                                                                                                                                                                                                                                                                         |  | <b>1</b>                                                                                                                                                                                                                                                                         |  |
| Random assignment of the patients to the intervention and control groups through the drawing of lots. To do this, we prepare two sheets and write "intervention" on one sheet and "control" on another. Then, by referring each patient, one of the sheets will be randomly taken and the patient will be assigned to the intervention or control group. |  | <b>Description</b>                                                                                                                                                                                                                                                               |  |
| <b>Blinding (investigator's opinion)</b>                                                                                                                                                                                                                                                                                                                 |  | Preeclampsia                                                                                                                                                                                                                                                                     |  |
| Single blinded                                                                                                                                                                                                                                                                                                                                           |  | <b>Timepoint</b>                                                                                                                                                                                                                                                                 |  |
| <b>Blinding description</b>                                                                                                                                                                                                                                                                                                                              |  | Every two weeks until the end of pregnancy                                                                                                                                                                                                                                       |  |
| The physician who will examine the patients will not be aware of the intervention. Thus, the trial will be run as single -blind.                                                                                                                                                                                                                         |  | <b>Method of measurement</b>                                                                                                                                                                                                                                                     |  |
| <b>Placebo</b>                                                                                                                                                                                                                                                                                                                                           |  | By taking a history (headache, blurred vision, epigastric pain, seizures), clinical examination (hypertension) and laboratory methods (oliguria, proteinuria, and increased liver enzymes)                                                                                       |  |
| Not used                                                                                                                                                                                                                                                                                                                                                 |  | <b>Secondary outcomes</b>                                                                                                                                                                                                                                                        |  |
| <b>Assignment</b>                                                                                                                                                                                                                                                                                                                                        |  | empty                                                                                                                                                                                                                                                                            |  |
| Parallel                                                                                                                                                                                                                                                                                                                                                 |  | <b>Intervention groups</b>                                                                                                                                                                                                                                                       |  |
| <b>Other design features</b>                                                                                                                                                                                                                                                                                                                             |  | <b>1</b>                                                                                                                                                                                                                                                                         |  |
| <b>Secondary Ids</b>                                                                                                                                                                                                                                                                                                                                     |  | <b>Description</b>                                                                                                                                                                                                                                                               |  |
| empty                                                                                                                                                                                                                                                                                                                                                    |  | Intervention group: Supplements (iron tablets and multivitamin capsules and calcium tablets) from 16th weeks of pregnancy once a day for 16 weeks plus L-arginine 500 mg tablets (manufactured by Karen Pharmaceutical Co.) from 20th weeks of pregnancy once a day for 12 weeks |  |
| <b>Ethics committees</b>                                                                                                                                                                                                                                                                                                                                 |  | <b>Category</b>                                                                                                                                                                                                                                                                  |  |
| <b>1</b>                                                                                                                                                                                                                                                                                                                                                 |  | Treatment - Drugs                                                                                                                                                                                                                                                                |  |
| <b>Ethics committee</b>                                                                                                                                                                                                                                                                                                                                  |  | <b>2</b>                                                                                                                                                                                                                                                                         |  |
| <b>Name of ethics committee</b>                                                                                                                                                                                                                                                                                                                          |  | <b>Description</b>                                                                                                                                                                                                                                                               |  |
| Ethics Committee of Hamadan University of Medical                                                                                                                                                                                                                                                                                                        |  |                                                                                                                                                                                                                                                                                  |  |

Control group: Supplements (iron tablets and multivitamin capsules and calcium tablets) from 16th weeks of pregnancy once a day for 16 weeks

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Fatemieh Hospital in Hamadan city

**Full name of responsible person**

Dr. Shahedeh Khansari

**Street address**

Fatemieh Hospital, Pasdaran Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3828 3939

**Email**

dr\_sh\_kh@yahoo.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Reza Shokoohi

**Street address**

Hamadan University of Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0717

**Email**

info.research@umsha.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Hamedan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Shahedeh Khansari

**Position**

Gynecologist

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

School of Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0572

**Email**

dr\_sh\_kh@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Shahla Nasrolahi

**Position**

Gynecologist

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

School of Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0572

**Email**

sh.nasrolahi@yahoo.com

## Person responsible for updating data

poorolajal@umsha.ac.ir

### Contact

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Jalal Poorolajal

**Position**

Professor of Epidemiology

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Epidemiology

**Street address**

School of Public Health, Hamadan University of  
Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0090

**Email**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available